Medical Device Manufacturing & Healthcare IT Solutions
Strategic Profile
Synektik holds strategic advantages through its partnership with Siemens, its proprietary PACS software platform for diagnostic imaging laboratories, and its multi-country operational presence including Poland, Czech Republic, and Slovakia. The company benefits from strong financial metrics including a 51.78% ROE, solid cash generation with PLN 42.12 million in free cash flow, and a dividend yield of 4.18%, positioning it as a profitable, cash-generative healthcare solutions provider.
Cyborg Score Rationale
Synektik demonstrates solid operational performance with strong profitability metrics (18.33% operating margin), excellent returns on equity, and positive market momentum (39.58% stock price increase over 52 weeks). The company maintains a healthy balance sheet with net cash position and diversified revenue streams across multiple countries, though scale remains modest relative to larger medical device competitors.
Top Insights
Strong profitability with 18.33% operating margin and 51.78% ROE indicates efficient capital deployment in a niche market
Siemens partnership provides competitive moat and market access for imaging solutions across Central Europe
Dividend yield of 4.18% combined with 39.58% YoY stock appreciation suggests market confidence in sustainable business model
PACS software and radiopharmaceutical products provide recurring revenue and switching cost advantages with healthcare customers
Named Competitors
Imaging Systems — Large multinational diagnostic imaging and medical device manufacturer
Diagnostic Imaging Systems — Global medical technology company with imaging and diagnostic focus
Healthcare Diagnostics — Multinational medical device and imaging conglomerate